Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery
New England Journal of Medicine2016Vol. 376(2), pp. 136–148
Citations Over TimeTop 1% of 2016 papers
Paul S. Myles, Julian A. Smith, Andrew Forbes, Brendan Silbert, Mohandas Jayarajah, Thomas Painter, D. James Cooper, Silvana Marasco, John J. McNeil, Jean S. Bussières, Shay McGuinness, Kelly Byrne, Matthew T.V. Chan, Giovanni Landoni, Sophie Wallace
Abstract
Among patients undergoing coronary-artery surgery, tranexamic acid was associated with a lower risk of bleeding than was placebo, without a higher risk of death or thrombotic complications within 30 days after surgery. Tranexamic acid was associated with a higher risk of postoperative seizures. (Funded by the Australian National Health and Medical Research Council and others; ATACAS Australia New Zealand Clinical Trials Registry number, ACTRN12605000557639 .).
Related Papers
- → Role of topical tranexamic acid in the management of idiopathic anterior epistaxis in adult patients in the emergency department(2016)18 cited
- → Tranexamic acid-induced fixed drug eruption(2015)6 cited
- → The effect of Tranexamic acid on cardiac surgery bleeding(2014)1 cited
- → Effects of Tranexamic Acid in Reducing Blood Loss in Patients Undergoing Coronary Artery Bypass Surgery: A Systematic Review(2020)
- Tranexamic Acid가 부인암 세포주 및 생쥐 신피막하에 이식된 암조직 성장에 미치는 영향(1989)